| __timestamp | CymaBay Therapeutics, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 2652041 |
| Thursday, January 1, 2015 | 8871000 | 2361587 |
| Friday, January 1, 2016 | 9645000 | 4472869 |
| Sunday, January 1, 2017 | 12387000 | 5030957 |
| Monday, January 1, 2018 | 14381000 | 4988941 |
| Tuesday, January 1, 2019 | 19238000 | 5196412 |
| Wednesday, January 1, 2020 | 17425000 | 6652774 |
| Friday, January 1, 2021 | 23040000 | 18418247 |
| Saturday, January 1, 2022 | 25116000 | 24827066 |
| Sunday, January 1, 2023 | 51953000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Cracking the code
In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Opthea Limited and CymaBay Therapeutics, Inc. from 2014 to 2023. Over this decade, CymaBay's SG&A expenses surged by over 500%, peaking in 2023, while Opthea's expenses increased by approximately 1,500%, reaching their zenith in 2022. Notably, CymaBay's expenses consistently outpaced Opthea's until 2022, when Opthea briefly surpassed CymaBay. This shift highlights Opthea's aggressive expansion strategy. However, in 2023, CymaBay reclaimed the lead, indicating a potential strategic pivot. Missing data for 2024 suggests ongoing financial adjustments. These trends underscore the evolving strategies of these biotech firms, reflecting their responses to market demands and growth opportunities.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Opthea Limited
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
BeiGene, Ltd. or Opthea Limited: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Insmed Incorporated vs CymaBay Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.